No Data
Novo Nordisk A/S and Eli Lilly and Co welcome heavy bullish news! It is rumored that weight loss drugs may enter the U.S. medical insurance system.
According to reports, the government led by usa President Biden is proposing a regulation that would require payment for weight loss drugs, potentially expanding access to these medications for millions of obese americans and creating a massive new medical bill for elected President Donald Trump.
Futu Morning Report | The US stock market party continues! The s&p 500 index has risen for seven consecutive days, setting a new historical high; Federal Reserve meeting minutes: future interest rate cuts will be cautious, and the end of monetary easing i
Market response to Trump's tariff threats: auto stocks wail, the Canadian dollar hits a four-year low, and the Mexican peso plunges nearly 3%; dell technologies drops over 10% after hours, with total net revenue for the third quarter at 24.37 billion USD, below analyst expectations.
Transaction volume TOP 20 | Bitcoin falls below 0.091 million dollars, microstrategy drops over 12%; eli lilly and co rises over 4%, the Biden administration plans to include weight loss drugs in the health insurance subsidy program.
On Tuesday, the stock trading volume leader was nvidia, which rose by 0.66% with a trading volume of 25.738 billion USD. nvidia announced on Monday the launch of its music-generating AI model, Fugatto, claiming it to be the "most flexible sound machine in the world," capable of precisely controlling sound generation. nvidia stated that this tool is like a "swiss army knife" for the sound field, being able to create music, modify sounds, and flexibly mix various music, vocals, and sound effects, even generating unprecedented sounds. The second place went to Tesla, which fell by 0.11% with a trading volume of 20.929 billion USD. ubs group published a bearish research report on Tesla. The institutions stated,
Amgen weight loss drugs have a remarkable effect of reducing 20% body weight, but with relatively high side effects, leading to a temporary large drop of over 12% during trading hours.
Although the weight loss effect of amgen's MariTide drug met expectations, the high side effects, lower than eli lilly and co's Zepbound, and the trial results falling below Wall Street's high expectations, led to amgen's stock price plunging over 12.3% on Tuesday, far behind eli lilly and co and novo-nordisk a/s, which benefited from the Biden policy rise at the same time. In a one-year trial, MariTide helped non-diabetic patients lose up to 20% of their weight, comparable to the maximum dose effect of eli lilly's Zepbound. However, the side effects are significant, with about 11% of patients dropping out of the trial due to side effects, higher than eli lilly's 7%.
US stocks closed | The three major indices rose together, with Dow Jones and S&P hitting new highs; tariff threats dragged down auto stocks, general motors fell 9%
Waiting for PCE inflation, the Fed's November minutes support gradual rate cuts, temporarily suppressing US bond yields and the dollar while gold rallies. The Dow turns higher at the end of the day, hitting new highs for three consecutive days, while small cap stocks fall from the highest level in six days, with chip stocks down more than 1%, but nvidia rebounds by 0.7%. Tesla reverses its decline, Nio falls by 7.7%, Amgen's weight loss drug once fell by more than 12%, and Dell falls more than 9% after hours.
Health Care Up as Ely Lilly Rallies on Medicare Proposal -- Health Care Roundup